The clinical high-risk state in psychosis is most often characterized by subthreshold psychotic symptoms (STPS) and represents a target for psychosis prevention. However, evidence suggests that between 30% and 50% of patients with a first episode of psychosis (FEP) report no prior history of STPS, indicating that not all patients with FEP experience a previous clinical high-risk phase. As with other early characteristics of illness onset, this diversity in the early course of symptoms may offer prognostic value for subsequent clinical trajectories.
I t is well accepted that specialized early intervention in the first 2 to 5 years of psychotic disorders, the putative "critical period," 1 can improve trajectories of illness and optimize long-term outcomes. [2] [3] [4] [5] [6] Conversely, a failure to intervene during the early stages of illness is thought to lead to poorer long-term outcomes. [7] [8] [9] This realization and the promise of initial studies regarding the early course of schizophrenia 10, 11 have led to the definition and widespread operationalization of stages of illness in psychosis research and clinical programming, 12 including the threshold-level first episode of psychosis (FEP); a retrospectively defined prodromal period of affective symptoms, anxiety symptoms, attentional symptoms, subthreshold psychotic symptoms (STPS), and/or other symptoms that runs continuously into FEP 13, 14 ; and, more recently, the prospectively defined clinical highrisk (CHR) state.
15, 16 The CHR state is most often characterized by STPS 17 and indicates increased risk for psychosis compared with the general population, 18,19 even though only a minority of cases experiencing a CHR state ultimately transition to FEP.
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Although a CHR state thus represents an important target for preventing or delaying the onset of psychosis [21] [22] [23] and other features of illness onset are associated with longitudinal trajectories, 13, [24] [25] [26] it remains unknown whether a history of pre-onset STPS (consistent with the CHR state) is associated with differential outcomes during treatment of FEP. Compared with patients with FEP presenting to services de novo, patients with FEP who had previously been treated for a CHR state had higher employment rates and lower rates of hospital admission. 27 Yet individuals able to access early intervention services at an earlier (CHR) stage may a priori be more likely to demonstrate improved outcomes relative to those who receive services only at a later (FEP) stage. Furthermore, services for those in a CHR state have a more limited reach than services for FEP: the vast majority of patients with FEP have not received specialized treatment for a CHR state. 28, 29 In addition to previous critiques of the CHR field, 28,29 these comparisons make the implicit assumption that services for a CHR state would have been indicated before the onset of any FEP. However, recent work has found that between 30% and 50% of cases of FEP appear to develop without any history of prior STPS, 30,31 indicating 2 potentially distinct subpopulations of patients with FEP. 32 Because not all patients with FEP experience pre-onset STPS, the focus on targeting these symptoms during a CHR phase (beyond the benefits of preventing or delaying psychosis) presumes that STPS have prognostic value over time. And since subpopulations of patients with or without STPS are similar in sociodemographics, symptoms, and functioning at intake for FEP services, 30 it is critical to know whether individuals reporting pre-onset STPS experience differential clinical outcomes during specialized early intervention for FEP.
The objective of the present study is, therefore, to determine whether a history of pre-onset STPS is associated with differential FEP treatment outcomes. We examined symptom severity and functioning 33,34 during 1 year of specialized early intervention for patients with FEP for whom the reported presence or absence of pre-onset STPS was routinely documented as part of an ongoing observational study situated in a catchment-based clinical service. 30 Based on known associations between prolonged durations of untreated (threshold-level) psychosis and less favorable outcomes, 7,35-40 we hypothesized that even after correcting for differences in treatment delay, patients with pre-onset STPS would exhibit greater psychotic symptoms and poorer functioning after 1 year of specialized early intervention for FEP than patients who did not experience STPS.
Methods

Setting
Patients who participated in this study were recruited between January 17, 2003, and October 17, 2013, from the Prevention and Early Intervention Program for Psychosis (PEPPMontreal), an early intervention clinic of the Douglas Mental Health University Institute that serves a catchment area of approximately 300 000 individuals in the southwest of Montreal, Québec, Canada. In keeping with recent guidelines, 41, 42 patients were treated with low-dose second-generation antipsychotic medications on a naturalistic basis. Dosage was recorded in chlorpromazine hydrochloride equivalents (dosage × adherence). In addition, patients received modified assertive case management and had access to referrals for family-focused treatment, individual cognitive behavioral therapy, and groups focused on anxiety and other psychosocial functioning. Patients were eligible to participate in PEPPMontreal's ongoing naturalistic, longitudinal research study if they (1) met the diagnostic criteria for a nonaffective (schizophrenia spectrum) or affective psychotic disorder (not attributable to substance use alone) based on the Structured Clinical Interview from the DSM-IV, 43 (2) had received less than 1 month of antipsychotic medication, (3) had an IQ of 70 or greater, (4) had no organic mental disorder (eg, epilepsy), and (5) were between 14 and 35 years of age. The research study was approved by the Douglas Mental Health University Institute's ethics review board. Participants provided written in-
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Question Do the outcomes of patients with a first episode of psychosis differ based on the experience of a prior clinical high-risk state?
Findings In this cohort study of 195 patients with a first episode of psychosis, those recalling pre-onset subthreshold psychotic symptoms presented similarly at baseline compared with patients without such a history, but they exhibited poorer psychotic symptom outcomes and functional outcomes after 1 year of specialized early intervention.
Meaning A history of subthreshold psychotic symptoms, consistent with a prior clinical high-risk state, is associated with poorer psychotic symptom outcomes and functional outcomes during treatment for a first episode of psychosis; the presence or absence of pre-onset subthreshold psychotic symptoms has prognostic value for treatment outcomes even during a later stage of psychosis.
formed consent, or assent with written parental consent if they were younger than 18 years.
Instruments
To 
30
Of 27 signs and symptoms, the following 9 were selected by international experts as constituting STPS "if they appeared at a time when an individual would not have met criteria for a syndromal level psychotic episode" 30(p1048) : suspiciousness or odd ideas of reference; odd or bizarre ideas that are not delusional; odd, unusual, or eccentric behavior; unusual perceptual experiences that are not clearly psychotic; disorganized or odd speech; inappropriate affect; hallucinations or delusions (subthreshold); and passivity experiences. As previously described, 30 range, 0-20) for each metric were calculated. Depression was evaluated with the Calgary Depression Scale for Schizophrenia (CDSS), 52 and anxiety was evaluated with the Hamilton Anxiety Rating Scale (HAM-A) 53 ; total scores (CDSS: range, 0-27; HAM-A: range, 0-54) were considered for analyses.
To assess functioning, the Social and Occupational Functioning Assessment Scale (SOFAS) 54 ) and baseline clinical scores (SAPS, SANS, GAF, SOFAS, CDSS and HAM-A) to compare the 195 participants who were included in the longitudinal analyses of outcomes with the remaining participants. Tests were similarly applied among the included sample of 195 participants to assess for sociodemographic differences between groups (STPSp vs STPSa). To examine medication dosage between groups, a mixed analysis of variance was applied to chlorpromazine equivalents across time points.
Because DUP, defined as the time elapsed between the start of a psychotic episode and the administration of antipsychotic medication, is an established predictor of outcome, [7] [8] [9] a Mann-Whitney test was applied to test group effects. It was decided a priori that if significant at P < .05, DUP would be included as a covariate in the analyses of covariance (ANCOVA) for the outcomes described.
To analyze changing symptoms and functioning, mixed ANCOVA, controlling for significant covariates, were applied with group (STPSp and STPSa) as the between-participants variable and time point (baseline and after 1 year of treatment) as the within-participants variable. The following 3 domains of outcome (and corresponding dependent variables) were considered: psychotic symptoms (SAPS and SANS), nonpsychotic symptoms (CDSS and HAM-A), and functioning (GAF and SOFAS). Bonferroni corrections were applied for multiple comparisons within each domain of outcome, yielding a P < .025 for significance.
Significant group-by-time interactions and main group effects were analyzed post hoc, with Bonferroni-corrected simple effects tests (P < .025) comparing groups at each time point. For all mixed analyses of variance and ANCOVA, GreenhouseGeisser corrections were applied to correct for sphericity violations.
Results
Sample Characteristics
No significant group differences in mean age at baseline evaluation, educational level, patient and parental socioeconomic status, ratio of affective to nonaffective cases, and medication dosage were observed between patients with STPSp and patients with STPSa included in longitudinal analyses (Table 1) . Furthermore, the total (combined STPSp and STPSa) sample included in the longitudinal analyses of outcome did not differ in age, sex, parental socioeconomic status, or most clinical characteristics at baseline from the sample excluded owing to incomplete STPS or other evaluations ( 
Duration of Untreated Psychosis
Patients who experienced subthreshold psychotic symptoms exhibited a significantly longer DUP than those who did not experience such symptoms (median, 17.6 weeks [interquartile range, 7.1-62.0 weeks] vs 11.4 weeks [interquartile range, 4.3-26.3 weeks]; P = .04; Table 1 ). As such, DUP was introduced as a covariate in subsequent analyses examining outcomes in symptoms and functioning.
Outcomes Psychotic Symptoms
Mixed ANCOVA of SAPS scores revealed main effects of time with decreasing scores (F 1,192 = 464; P < .001) and of group (F 1,192 = 5.31; P = .02), whereby patients with STPSp exhibited higher SAPS scores. Analyses of SANS scores also revealed a significant group-by-time interaction (F 1,192 = 6.17; P = .01). Post hoc simple effects tests comparing STPSp and STPSa groups at each time point revealed no differences at baseline, but showed that patients with STPSp exhibited higher 
Research Original Investigation
Pre-onset Subthreshold Psychotic Symptoms and Treatment Outcomes for a First Episode of Psychosis SAPS and SANS scores after 1 year of treatment (Table 3 and Figure) .
Nonpsychotic Symptoms
Mixed ANCOVA of CDSS scores revealed significant main effects of time only, showing score reductions over time (F 1,192 = 44.8; P < .001; Table 3 and Figure) . Mixed ANCOVA of HAM-A scores also revealed score reductions over time (F 1,182 = 91.8; P < .001).
Functioning
Mixed ANCOVA on scales of functioning revealed a significant group-by-time interaction for GAF scores (F 1,188 = 7.54; P = .006). For SOFAS scores (F 1,192 = 3.79; P = .05), the trend toward significance disappeared after correction for multiple comparisons, and a significant effect of time only remained (F 1,192 = 241; P < .001). Post hoc simple effects tests comparing groups at time points revealed that only after 1 year of treatment, the STPSp group exhibited significantly lower scores than the STPSa group on the GAF (Table 3 and Figure) .
Discussion
The present study investigated symptom severity and functioning at baseline and after 1 year of specialized early intervention in patients with FEP with or without a history of STPS. These groups exhibited few differences at baseline, 30 and both demonstrated substantial recovery over time for all outcomes examined (Figure) ; however, notable differences emerged in the severity of positive and negative psychotic symptoms as well as functioning after 1 year. The divergent trajectories were not explained by depression or anxiety, nor by treatment delays reflected in DUP. All significant and trending findings suggest, to our knowledge for the first time, that a history of pre-onset STPS (consistent with a CHR state) is as- sociated with poorer symptomatic and functional recovery during treatment for FEP, with implications for prognosis and early intervention across stages of early psychosis. While there were no differences in SOFAS scores at baseline, at year 1 the STPSp group achieved SOFAS scores bordering between moderate difficulty (scores, 51-60) and some difficulty (scores, 61-70), whereas the STPSa group crossed this clinical threshold (Table 3 ). This distinction is relevant because scores of 61 or higher are considered among the criteria for functional remission. 58, 59 Although this group-by-time interaction was statistically nonsignificant after controlling for multiple comparisons, a longer follow-up period may reveal the association between STPS history and functioning to be meaningful. This is unsurprising when considering that functional outcome improvements (which include vocational attainment such as employment and education) are likely to lag behind remission of symptoms. Analyses of GAF scores after 1 year of treatment also support a clinically significant group effect: the patients with STPSa achieved scores above the threshold for functional remission (≥61), 58, 60, 61 whereas the patients with STPSp were well below this threshold ( Table 3) . The overall direction of the results for psychotic symptoms is congruent with those regarding functioning. For example, the decreasing summary SAPS and SANS scores can reliably be interpreted as globally reduced symptoms over time. 51 Furthermore, while there was no significant group-by-time interaction for SAPS, our post hoc tests indicate that the STPSp group had relatively higher positive psychotic symptoms after 1 year of FEP services. The larger between-group differences seen in GAF scores compared with SOFAS scores after 1 year of treatment (and the integration of symptoms into the former) suggests that further examination of whether symptomatic differences are more substantive or persistent than functional differences may be warranted.
A range of factors could be invoked to explain the relatively poorer longitudinal outcomes observed for patients with STPSp and/or the improved outcomes seen for patients with STPSa. For example, the experience of pre-onset STPS may demarcate a unique form, or biotype, of psychosis, 62 which could be explored by studying diverse variables such as cognition, brain morphologic characteristics, or therapeutic response in a multidimensional data set. Alternatively, examining care pathways and treatment delays may shed light on other variables contributing to our findings. Given the established association between DUP and FEP outcomes, exposure to preonset STPS may represent an "extended DUP" (combining both threshold and subtheshold psychotic symptoms). The extended DUP concept, acting through biological and/or psychosocial mechanisms, [63] [64] [65] could further explain the poorer recovery seen in the STPSp group, whereas patients with STPSa b Significant pairwise comparison, Bonferroni corrected (P < .025).
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may have a relatively acute-onset psychosis with a shorter threshold-level DUP followed by rapid recovery. The association between STPS and poorer 1-year outcomes is strengthened by the fact that our analyses addressed potential confounders of this association. The STPSp and STPSa groups were similar in symptoms of depression and anxiety at baseline and 1 year (Figure) , had equivalent exposure to antipsychotic medications (Table 1) , and demonstrated no differences in other clinical or sociodemographic factors at baseline (eg, educational level or affective vs nonaffective psychosis) (Table 1) . Furthermore, our analysis controlled for differences in DUP (a known predictor of outcome). [7] [8] [9] For clinicians, this study is the first, to our knowledge, to provide evidence that pre-onset symptoms consistent with the CHR phase (vs lack thereof) have a differential imprint on the clinical course in a subsequent threshold-level (FEP) stage of illness. It implies that inquiring about preonset STPS when a patient is seeking help for FEP can reveal important information regarding prognosis, and it suggests that more intensive or tailored efforts during treatment for FEP should be considered to improve functional and not just symptomatic outcomes for patients with prior STPS. Our approach also offers insights for prevention and early intervention during the CHR stage itself. For example, as in most community settings, 28,29 patients with STPSp in this study received no organized early intervention for those symptoms, even though they may have received individual components of evidence-based treatment for the CHR phase (such as cognitive behavioral therapy) in a non-early intervention context. 66 While multiple early psychopathologic or other factors can contribute to long-term treatment outcomes, the presence or absence of pre-onset STPS appears to be an important (although not necessarily causal) prognostic marker for patients who transition to FEP. This complements arguments that multicomponent interventions aimed at the CHR stage should attempt to target and improve both symptoms and functioning, 67 and raises the possibility that increasing the spread and reach of comprehensive services for the CHR state could ameliorate such difficulties among future patients who transition from a CHR state to FEP. In addition, viewing STPS and the CHR syndrome through the lens of FEP clinical populations could begin to address recent critiques of the CHR construct and its operationalization, 68,69 such as the recognition that transitions to FEP can develop across diagnostic silos rather than solely following a CHR state. This finding, too, has servicelevel implications: because not all patients with FEP experience pre-onset STPS, CHR services as currently constructed have an upper limit on their ability to identify and prevent transitions to psychosis. Prevention and early intervention efforts may therefore need to begin considering how to identify non-STPS syndromes that could transition to psychosis.
Strengths and Limitations
A strength of this study is that the data were collected from the sole specialized early FEP intervention program within a local catchment area-one that has conducted wide outreach activities 70 and is well recognized in the community-and are therefore likely to be epidemiologically representative. 71 Furthermore, with the exception of education, no significant differences in baseline clinical and sociodemographic characteristics were found between the sample of participants included in the present study and the sample of participants who were excluded owing to incomplete data ( Table 2 ). This finding suggests that the 195 patients studied (whose STPS status and outcomes were both identified and data were available) were reasonably representative of the total clinical population being served and that the findings are relatively generalizable. Previous work examining early psychiatric signs and their association with threshold-level psychosishas established that insidious-onset forms of psychosis are (compared with acuteonset forms) associated with poorer outcomes. 14, 24, [72] [73] [74] [75] In such studies, onset is frequently characterized by any noticeable behavioral change (including affective or negative symptoms) 13 
Conclusions
Building on recent findings that between 30% and 50% of FEP cases develop without pre-onset STPS, 30,31 our results provide novel evidence for poorer prognosis in both psychotic symptoms and global functioning during the first year of specialized early intervention in patients who had an FEP with prior STPS (consistent with a CHR state). This implies that the imprint of STPS extends to outcomes in later stages, is not explained by comorbid conditions or treatment delays, and suggests that prevention and early intervention efforts in the CHR and FEP phases should increasingly target functioning alongside psychotic symptoms. 
